Arbutus Says Discontinuing All Coronavirus And Oral RNA Destabilizer Programs, Including AB-343 And AB-161; Expects Pipeline Changes To Extend Cash Runway Through Q3 2025
Portfolio Pulse from Benzinga Newsdesk
Arbutus Biopharma Corporation has announced that it will discontinue all its coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161. The company expects these pipeline changes to extend its cash runway through Q3 2025.
September 11, 2023 | 8:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arbutus Biopharma's decision to discontinue its coronavirus and oral RNA destabilizer programs could potentially impact its stock price. The move is expected to extend the company's cash runway through Q3 2025.
Arbutus Biopharma's decision to discontinue its coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161, could be seen as a negative development by investors, potentially leading to a decrease in the company's stock price. However, the company expects these changes to extend its cash runway through Q3 2025, which could be viewed positively by investors in the long term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100